Chemically modified short interfering nucleic acid molecules that mediate rna interference

Details for Australian Patent Application No. 2006279454 (hide)

Owner Sirna Therapeutics, Inc.

Inventors McSwiggen, James; Morisey, David; Beigelman, Leonid

Agent Spruson & Ferguson

Pub. Number AU-B-2006279454

PCT Pub. Number WO2007/022369

Priority 60/737,024 15.11.05 US; 11/299,254 08.12.05 US; 11/205,646 17.08.05 US; 11/234,730 23.09.05 US

Filing date 17 August 2006

Wipo publication date 22 February 2007

Acceptance publication date 15 December 2011

International Classifications

C07K 14/02 (2006.01) Peptides having more than 20 amino acids

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

13 March 2008 PCT application entered the National Phase

  PCT publication WO2007/022369 Priority application(s): WO2007/022369

15 December 2011 Application Accepted

  Published as AU-B-2006279454

12 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006279462-Modified VEGF and PDGF with improved angiogenic properties

2006279441-Drug-surfactant complexes for sustained release